FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient recruitment for the phase 1 trial will begin soon (NCT06913608). The phase 1 clinical trial will evaluate the safety and efficacy of CLBR001 + SWI019 in patients with myositis, systemic sclerosis, lupus and rheumatoid arthritis, with the potential to expand to other indications in the future.
from Top Health News -- ScienceDaily https://ift.tt/C4qyEcO
Subscribe to:
Post Comments (Atom)
-
Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response with just one ...
-
Researchers observed a rise in adult central nervous system (CNS) infections, primarily aseptic meningitis caused by the varicella zoster vi...
-
Three treaties between the US and Hong Kong were suspended, the latest move to pressure China. from Yahoo News - Latest News & Headl...
No comments:
Post a Comment